Furthermore, assessment of mRNA from ASO-treated primary hBE cells from a patient with CFTR-W1282X and CFTR-F508del revealed partial allele specificity of ASO-induced exon 23 skipping for CFTR-W1282X (SI Appendix, Fig. S3), potentially broadening the scope of this ASO strategy to CF patients heterozygous for CFTR-W1282X and another CFTR mutation less responsive to current modulator therapies. The gene discussed is CFTR; the disease is cystic fibrosis.